Stephanie Archer is a Contributing Writer at Film Inquiry, PLOS, and NEOMERS. She focuses on the film industry and filmmaking, exploring the intricacies and narratives within these creative domains. Her work has been featured in various reputable publications, showcasing her insights and expertise in the cinematic landscape.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Stephanie Archer's coverage primarily focuses on event coverage, particularly related to film festivals and horror films. She appears to have a keen interest in reviewing movies showcased at these events. Given this focus, she may be receptive to pitches related to exclusive interviews or behind-the-scenes insights into the making of horror films featured at film festivals.
Additionally, Stephanie covers gaming, entertainment news, house & home, and culture & society themes. Pitches that align with these topics but are tailored towards her primary focus on film inquiries could also be well-received.
As Stephanie does not appear to have a specific geographic focus mentioned, it is likely that she is interested in worldwide events within the realm of film festivals and horror films.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lucy Raymond, David H. Rowitch, Malachy Bromham, Stephanie Archer, Sophie Rowitch, Sara O Curry, Helen Dolling, Claire Hughes, Kate Baker
Abstract As early rapid genomic sequencing (rGS) is adopted in paediatric medicine, there is an urgency to understand and address family support needs.
By: Stephen Morris, Francisca Stutzin Donoso, Cameron Wilson, Amy Lafont, Laura Stylianou, Lorenzo Ficorella, Marc Tischkowitz, Jon Emery, Fiona M. Walter, Adam E. Stokes, Jack Broome, Antonis C. Antoniou, Tim Carver, Stephanie Archer, Juliet A. Usher-Smith, Joe Dennis
Background CanRisk is a risk assessment tool that implements the BOADICEA multifactorial breast cancer risk model. The BOADICEA model is recommended for use by the National Institute for Health and Care Excellence (NICE) in English, Welsh, and Northern Irish secondary/tertiary care to identify women who may be at moderate or high risk of developing breast cancer. BOADICEA combines information on cancer family history, demographic, lifestyle, hormonal risk factors and mammographic density with polygenic scores (PGS). Offering risk assessment using CanRisk in general practice has the potential to identify more women at moderate or high risk of developing breast cancer and improve their management and the appropriateness of referrals to secondary/tertiary care. Materials and methods In this feasibility study we plan to invite women aged 40–49 years from 5–8 practices across Cambridgeshire and Peterborough in England, UK to complete a breast cancer risk assessment using CanRisk via a newly developed public-facing version of the CanRisk tool and provide saliva samples for PGS. The study team will provide a risk report back to both the participants and their GP, with those women at above-population level risk advised to make an appointment with their GP to be referred to the clinical genetics service and subsequently managed in line with current NICE guidelines. This study will provide evidence on (1) whether offering cancer risk assessment including PGS in general practice is feasible and acceptable to women and healthcare professionals; (2) whether this approach can identify women at above-population level risk of breast cancer who would otherwise not have been identified and so not had access to risk-reducing options; and (3) the costs associated with implementing proactive multifactorial breast cancer risk assessment in women under 50 within general practice. Study registration number This study is listed on the ISRCTN registry. The registration number is ISRCTN17376192.
